Bioject Medical Technologies In (BJCT) 0.0001 $BJCT
Inovio Pharmaceuticals Completes Acquisition of Needle-Free Injection Technology
GlobeNewswire - Mon May 02, 6:34AM CDT
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it has closed the transaction to acquire all of BioJect Medical Technologies Inc.'s assets, including pioneering needle-free jet injection technology, devices, and intellectual property, which it first announced in a definitive agreement on March 14, 2016. Inovio acquired BioJect for $4.3 million in Inovio common stock and $1.2 million in cash.
INO: 9.65 (+0.10)
Advanced Proteome Appoints Dr. Randal Chase to Its Board
Marketwired - Tue Jun 02, 8:04AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce the appointment of Dr. Randal Chase to its Board of Directors. Dr. Chase currently serves as Chairman of MediMabs, a privately held company, and is a member of the Board of Geovax Labs, Inc., a vaccine company trading on the OTCQX.
NVX: 16.70 (+0.05), APC.VN: 0.055 (-0.010)
Global Needle-free Drug Delivery Technologies market 2015-2019: Key Vendors are 3M, Antares Pharma, Bioject Medical Technologies, Glide Pharmaceutical Technologies, PharmaJet and Zogenix
PR Newswire Europe - Wed Jan 28, 10:25AM CST
DUBLIN, Jan. 27, 2015 /PRNewswire/ --Research and Markets
ATRS: 1.00 (-0.01)
Global Needle-free Drug Delivery Technologies market 2015-2019 3M, Antares Pharma, Bioject Medical Technologies, Glide Pharmaceutical Technologies, PharmaJet & Zogenix Dominating
M2 - Thu Jan 15, 4:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/rt6m7j/global) has announced the addition of the "Global Needle-free Drug Delivery Technologies market 2015-2019" report to their offering. The Global Needle-free Drug Delivery Technologies market to grow at a CAGR of 13.5% over the period 2014-2019 This report covers the present scenario and the growth prospects of the Global Needle-free Drug Delivery Technologies market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various needle-free drug delivery systems with active mechanisms for skin permeation such as velocity, ultrasound, iontophoresis, thermo ablation, and electrophoresis. The introduction and enforcement of various laws mandating the use of safety needles/syringes and needle-free devices are one of the major trends in this market. With the introduction and enforcement of such laws, the Healthcare and Pharmaceuticals markets worldwide are now switching to the mandatory use of safety needles/syringes and needle-free devices to help protect those at risk of infection from NSIs and other unsafe injection practices. According to the report, increased safety and efficiency are the key factors responsible for the growth of the market. Needle-free drug delivery systems provide better acceptability, particularly in self-administration settings. Further, the report states that needle-free drug delivery systems are associated with increased technology because of which there is a decrease in the rate of adoption. These devices require training modules and instruction manuals for the users. This mode of drug delivery includes: - Jet Injectors - Transdermal Patches (Microneedles, Nanopatches) Key Vendors - 3M - Antares Pharma - Bioject Medical Technologies - Glide Pharmaceutical Technologies - PharmaJet - Zogenix For more information visit http://www.researchandmarkets.com/research/rt6m7j/global
ATRS: 1.00 (-0.01)
Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines
PRWeb - Fri Dec 19, 8:03AM CST
Bioject Medical Technologies Inc. (OTC Pink: BJCT), a leading developer and manufacturer of needle-free injection technology, today announced that it has entered into an agreement with Immunomic Therapeutics, Inc. ("ITI" for ITI to use the Bioject's Biojector(R)-2000 needle-free injection device with its LAMP™ vaccine platform.
Inovio Pharmaceuticals Completes Acquisition of Needle-Free Injection Technology
GlobeNewswire - Mon May 02, 6:34AM CDT
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it has closed the transaction to acquire all of BioJect Medical Technologies Inc.'s assets, including pioneering needle-free jet injection technology, devices, and intellectual property, which it first announced in a definitive agreement on March 14, 2016. Inovio acquired BioJect for $4.3 million in Inovio common stock and $1.2 million in cash.
INO: 9.65 (+0.10)
Advanced Proteome Appoints Dr. Randal Chase to Its Board
Marketwired - Tue Jun 02, 8:04AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce the appointment of Dr. Randal Chase to its Board of Directors. Dr. Chase currently serves as Chairman of MediMabs, a privately held company, and is a member of the Board of Geovax Labs, Inc., a vaccine company trading on the OTCQX. NVX: 16.70 (+0.05), APC.VN: 0.055 (-0.010)
Global Needle-free Drug Delivery Technologies market 2015-2019: Key Vendors are 3M, Antares Pharma, Bioject Medical Technologies, Glide Pharmaceutical Technologies, PharmaJet and Zogenix
PR Newswire Europe - Wed Jan 28, 10:25AM CST
DUBLIN, Jan. 27, 2015 /PRNewswire/ --Research and Markets
ATRS: 1.00 (-0.01)
Global Needle-free Drug Delivery Technologies market 2015-2019 3M, Antares Pharma, Bioject Medical Technologies, Glide Pharmaceutical Technologies, PharmaJet & Zogenix Dominating
M2 - Thu Jan 15, 4:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/rt6m7j/global) has announced the addition of the "Global Needle-free Drug Delivery Technologies market 2015-2019" report to their offering. The Global Needle-free Drug Delivery Technologies market to grow at a CAGR of 13.5% over the period 2014-2019 This report covers the present scenario and the growth prospects of the Global Needle-free Drug Delivery Technologies market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various needle-free drug delivery systems with active mechanisms for skin permeation such as velocity, ultrasound, iontophoresis, thermo ablation, and electrophoresis. The introduction and enforcement of various laws mandating the use of safety needles/syringes and needle-free devices are one of the major trends in this market. With the introduction and enforcement of such laws, the Healthcare and Pharmaceuticals markets worldwide are now switching to the mandatory use of safety needles/syringes and needle-free devices to help protect those at risk of infection from NSIs and other unsafe injection practices. According to the report, increased safety and efficiency are the key factors responsible for the growth of the market. Needle-free drug delivery systems provide better acceptability, particularly in self-administration settings. Further, the report states that needle-free drug delivery systems are associated with increased technology because of which there is a decrease in the rate of adoption. These devices require training modules and instruction manuals for the users. This mode of drug delivery includes: - Jet Injectors - Transdermal Patches (Microneedles, Nanopatches) Key Vendors - 3M - Antares Pharma - Bioject Medical Technologies - Glide Pharmaceutical Technologies - PharmaJet - Zogenix For more information visit http://www.researchandmarkets.com/research/rt6m7j/global
ATRS: 1.00 (-0.01)
Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines
PRWeb - Fri Dec 19, 8:03AM CST
Bioject Medical Technologies Inc. (OTC Pink: BJCT), a leading developer and manufacturer of needle-free injection technology, today announced that it has entered into an agreement with Immunomic Therapeutics, Inc. ("ITI"
for ITI to use the Bioject's Biojector(R)-2000 needle-free injection device with its LAMP™ vaccine platform. 
